As of 2024-12-12, the Relative Valuation of Enanta Pharmaceuticals Inc (ENTA) is (118.02) USD. This relative valuation is based on P/E multiples. With the latest stock price at 7.00 USD, the upside of Enanta Pharmaceuticals Inc based on Relative Valuation is -1786.0%.
The range of the Relative Valuation is (89.36) - (152.01) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.8x - 35.5x | 26.5x |
| Forward P/E multiples | 20.1x - 34.3x | 26.7x |
| Fair Price | (89.36) - (152.01) | (118.02) |
| Upside | -1376.6% - -2271.5% | -1786.0% |
| Date | P/E |
| 2024-12-11 | -1.63 |
| 2024-12-10 | -1.95 |
| 2024-12-09 | -2.01 |
| 2024-12-06 | -1.80 |
| 2024-12-05 | -1.81 |
| 2024-12-04 | -1.92 |
| 2024-12-03 | -1.97 |
| 2024-12-02 | -1.93 |
| 2024-11-29 | -1.94 |
| 2024-11-27 | -1.99 |
| 2024-11-26 | -1.93 |
| 2024-11-25 | -2.03 |
| 2024-11-22 | -2.11 |
| 2024-11-21 | -2.10 |
| 2024-11-20 | -2.05 |
| 2024-11-19 | -2.12 |
| 2024-11-18 | -2.16 |
| 2024-11-15 | -2.15 |
| 2024-11-14 | -2.28 |
| 2024-11-13 | -2.35 |
| 2024-11-12 | -2.40 |
| 2024-11-11 | -2.45 |
| 2024-11-08 | -2.49 |
| 2024-11-07 | -2.56 |
| 2024-11-06 | -2.60 |
| 2024-11-05 | -2.54 |
| 2024-11-04 | -2.50 |
| 2024-11-01 | -2.47 |
| 2024-10-31 | -2.53 |
| 2024-10-30 | -2.59 |
| 2024-10-29 | -2.59 |
| 2024-10-28 | -2.61 |
| 2024-10-25 | -2.63 |
| 2024-10-24 | -2.74 |
| 2024-10-23 | -2.87 |
| 2024-10-22 | -2.93 |
| 2024-10-21 | -2.85 |
| 2024-10-18 | -2.85 |
| 2024-10-17 | -2.77 |
| 2024-10-16 | -2.73 |
| 2024-10-15 | -2.63 |
| 2024-10-14 | -2.55 |
| 2024-10-11 | -2.49 |
| 2024-10-10 | -2.40 |
| 2024-10-09 | -2.41 |
| 2024-10-08 | -2.48 |
| 2024-10-07 | -2.60 |
| 2024-10-04 | -2.57 |
| 2024-10-03 | -2.52 |
| 2024-10-02 | -2.54 |